[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Assiut University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":588},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,1274,0,25,[9,39,59,85,104,127,150,173,200,221,242,263,286,313,345,376,395,415,439,461,476,497,516,536,560],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100053943","outcomes-of-left-subclavian-artery-revascularization-strategies-during-zone-2-thoracic-endovascular-aortic-repair-100053943",false,"NCT07697820","Outcomes of Left Subclavian Artery Revascularization Strategies During Zone 2 Thoracic Endovascular Aortic Repair","Inclusion Criteria:\n\nPatients ≥18 years Undergoing TEVAR with proximal landing in zone 2 whether acute or chronic type B aortic dissection (TBAD), thoraco-abdominal aortic aneurysm (TAAA), penetrating aortic ulcer (PAU) or intramural hematoma (IMH).\n\n• Treatment with one of the following:\n\n* Single-branched stent grafts\n* In-situ fenestration (e.g. ISLF ± stent)\n* Chimney\u002Fperiscope graft techniques\n* Physician-modified endografts (PMEGs)\n* Carotid-subclavian bypass, carotid-axillary bypass, or subclavian transposition\n\nExclusion Criteria:\n\n* • Non revascularized left subclavian artery.\n\n  * Zone 0 or 1 procedures\n  * Multi-vessel arch debranching\n  * Blunt traumatic aortic injury (BTAI)\n  * Incomplete imaging or follow-up data","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","Intentional coverage of left subclavian artery (LSA) is often necessary during thoracic endovascular aortic repair (TEVAR) to secure an adequate proximal landing zone. However, this may impair blood flow to vital vascular territories with increased risk of stroke, spinal cord ischemia and upper limb ischemia.\n\nCurrent recommendations from the Society for Vascular Surgery (SVS) and European Society for Vascular Surgery (ESVS) support the consideration of LSA revascularization in patients undergoing elective TEVAR with anticipated LSA coverage. In contrast, management in the acute setting is more complex and requires an individualized approach based on clinical urgency and anatomical factors. Revascularization is generally recommended in high-risk clinical scenarios, including patients with dominant left vertebral circulation, compromised or occluded contralateral vertebral artery, an incomplete circle of Willis, or variant vertebral anatomy such as a hypoplastic left vertebral artery terminating in the posterior inferior cerebellar artery or an isolated vertebral artery. Additional indications include prior LIMA grafting, the presence of upper limb dialysis access, anticipated extensive aortic coverage, or an aberrant right subclavian artery in which both subclavian origins may be compromised.\n\nRevascularization techniques encompass both open surgical and endovascular approaches. Surgical options include carotid-subclavian bypass, carotid-axillary bypass, and subclavian transposition, while endovascular methods involve branched or fenestrated endografts, chimney and periscope grafts, as well as in situ fenestration. Although surgical techniques provide durable long-term patency, they are associated with a risk of local complications. Endovascular approaches are minimally invasive; however, they may be associated with an increased risk of endoleaks.\n\nAnatomical factors also play a central role in determining both the feasibility and outcomes. Preoperative assessment using computed tomography angiography is essential to evaluate aortic arch morphology, proximal landing zone characteristics, branch vessel orientation, and access vessel suitability. In addition, the spatial relationship between the left common carotid artery (LCCA) and LSA, including minimum inter-vessel distances, directly influences the feasibility of branched or fenestrated endografts. Also branch vessel anatomy is equally critical, as LSA diameter, vertebral artery origin, and vessel length determine the suitability for branch incorporation or fenestration techniques. Furthermore, access-related anatomical constraints, particularly iliofemoral vessel diameter and calcification, may significantly limit device delivery.",[26],"Aortic Aneurysm and Dissection","NOT_YET_RECRUITING","2026-07-10",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":20},"2026-10-01",{"date":35,"type":20},"2028-12-01",{"name":37,"class":38},"Assiut University","OTHER",{"id":40,"slug":41,"hasResults":12,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":4},"100053780","splanchnic-perfusion-monitoring-in-septic-shock-using-doppler-ultrasound-100053780","NCT07698834","Splanchnic Perfusion Monitoring in Septic Shock Using Doppler Ultrasound","Splanchnic Perfusion Monitoring Using Doppler Ultrasound in Septic Shock Patients: Correlation With Lactate Clearance, Organ Dysfunction, and Enteral Feeding Intolerance","Inclusion Criteria:\n\n* 1\\. Adult patients (≥18 years). 2. ICU admission with septic shock (Sepsis-3 definitions).\n\nExclusion Criteria:\n\n\\- 1. Advanced chronic liver disease. 2. Portal vein thrombosis. 3. Mesenteric ischemia (or clinical suspicion strongly suggesting it). 4. Severe right-sided heart failure. 5. Pregnancy. 6. Morbid obesity or any condition causing poor\u002Funsafe ultrasound acoustic window.\n\n7\\. Intra-abdominal conditions preventing adequate Doppler assessment. 8. Limitation of care \u002F do-not-resuscitate orders. 9. Pre-existing major gastrointestinal bleeding\u002Fobstruction if that is relevant to enteral feeding intolerance outcomes in your ICU.",{"count":47,"type":20},80,"OBSERVATIONAL","evaluation whether splanchnic Doppler ultrasound indices (SMA resistive index, portal vein pulsatility fraction, hepatic artery resistive index\u002Fflow parameters) can:\n\n1. Reflect regional tissue perfusion in septic shock, as correlated with lactate clearance.\n2. Associate with organ dysfunction severity and progression (SOFA dynamics).\n3. Predict enteral feeding intolerance in ICU patients receiving enteral nutrition",[51],"Septic Shock","2026-07-07",{"date":30,"type":31},{"date":55,"type":20},"2026-09",{"date":57,"type":20},"2027-10",{"name":37,"class":38},{"id":60,"slug":61,"hasResults":12,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":16,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":71,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100635288","effect-of-pressure-controlled-volume-guaranteed-versus-volume-controlled-ventilation-modes-on-hemodynamic-outcomes-eg--sv-co--and-respiratory-mechanics-during-laparoscopic-abdominal-cancer-surgeries-with-exaggerated-trendelenberg-postion-100635288","NCT07550738","Effect of Pressure-Controlled Volume Guaranteed Versus Volume-Controlled Ventilation Modes on Hemodynamic Outcomes e.g ( SV, CO ) and Respiratory Mechanics During Laparoscopic Abdominal Cancer Surgeries With Exaggerated Trendelenberg Postion","Effect of Pressure-Controlled Volume Guaranteed Versus Volume-Controlled Ventilation Modes on Hemodynamic Outcomes and Respiratory Mechanics During Laparoscopic Abdominal Cancer Surgeries With Exaggerated Trendelenberg Postion : A Randomized Controlled Trial","Inclusion Criteria:\n\n1 - All patients who will be scheduled for elective laparoscopic abdominal cancer surgeries 2- patients aged 20-80 years 3- patients have an American Society of Anesthesiologists (ASA) physical status I-II\n\nExclusion Criteria:\n\n1 - Patients with severe systemic disease (history of myocardial infarction, chronic obstructive, or restrictive lung disease) 2- Obese patients (BMI \\> 30) 3- patients with neurologic or neuromuscular diseases.",true,"20 Years","80 Years",{"count":70,"type":20},60,[23],"The primary outcome is to compare the hemodynamic outcomes ( e.g SV , CO and CI ) using The ICON of two different modes of ventilation ( VCV and PC-VG ) during laparoscopic abdominal cancer surgeries with exaggerated trendelenburg position.\n\nAnd the secondary outcomes is to compare the respiratory effects ( e.g atelectasis development , plateau pressure(Pplat) , peak inspiratory pressure(PIP) , dyn. compliance and postoperative inflammatory indicators e.g CRP and WBCs ) of two different modes of ventilation ( VCV and PC-VG ) during laparoscopic abdominal cancer surgeries with exaggerated trendelenburg position.",[74],"PCV-VG Versus VCV Ventilation Mode Effects on Hemodynamics","RECRUITING","2026-07-01",{"date":78,"type":31},"2026-07-02",{"date":80,"type":31},"2026-04-01",{"date":82,"type":20},"2027-06",{"name":37,"class":38},1,{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":66,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":91,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":84},"100585095","basic-hematological-parameters-and-coagulation-profile-in-type-1-diabetic-children-100585095","NCT06897904","Basic Hematological Parameters and Coagulation Profile in Type 1 Diabetic Children","Inclusion Criteria:\n\n* Age from one month to 18 year.\n* Both sexes.\n* Patients known to have type 1 diabetes.\n\nExclusion Criteria:\n\n* Patients less than one month and more than 18years.\n* history of bleeding disorders or anemia unrelated to diabetes.\n* Otherc types of diabetes .",{"count":92,"type":20},110,"Diabetes mellitus is a group of chronic metabolic diseases characterized by hyperglycemia .Type 1 diabetes is a heterogeneous disease related to the destruction of pancreatic beta cells and is a result of absolute lack of insulin\n\n* Diabetes mellitus has been traditionally looked upon as a disease of adults (except Type I diabetes), however it can affect individuals of any age. Given the peculiarities and problems that it carries, diabetes in children and adolescents poses special challenges to the entire society. Diabetes is the second commonest chronic disease occurring in 1 in every 1500 children by age 5 and in 1 in 350 children by age 8 . Microvascular (retinopathy, neuropathy, and nephropathy) Aim of the research to assess basic hematological parameters and coagulation profiles among type 1 diabetic children and compare them with healthy controls and macrovascular (coronary artery disease, peripheral vascular disease, and cerebrovascular disease) atherothrombotic complications may occur in children and adolescents, depending on the duration of diabetes, the degree of metabolic control, and other factorssuch as genetics . Diabetes mellitus can cause blood disorders such as deformity of red blood cells and increase their adhesion \\[6\\].It has an effect on the function of red blood cells through the interaction with the membrane and intracellular components . Red blood cell distribution width (RDW) is a measure of the difference in the size of red blood cells. An increase in RDW can be caused by anemia or nutritional deficiencies related to anemia\n* Studies have shown that the average number of red blood cells, hemoglobin and hematocrit in diabetic patients is lower than the control group, which indicates the presence of anemia in diabetic patients .",[95],"Type 1 Diabetes Mellitus","2026-06-29",{"date":98,"type":31},"2026-06-30",{"date":100,"type":31},"2025-04-01",{"date":102,"type":20},"2026-08-01",{"name":37,"class":38},{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":66,"sex":111,"minAge":17,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100644936","patterns-of-aortic-isthmus-doppler-in-early-fetal-growth-restriction--and-the-changes-in-aortic-isthmus-doppler-parameters-with-every-changes-of-other-early-iugr-parameters-like-efw-uterine-artery-doppler-cerebroplacental-ratio-and-ductus-venosus-doppler-in-comparison-with-normal-group--100644936","NCT07676708","Patterns of Aortic Isthmus Doppler in Early Fetal Growth Restriction , and the Changes in Aortic Isthmus Doppler Parameters With Every Changes of Other Early Iugr Parameters Like EFW, Uterine Artery Doppler, Cerebroplacental Ratio and Ductus Venosus Doppler in Comparison With Normal Group .","Patterns of Aortic Isthmus Doppler in Early Fetal Growth Restriction, Cross Sectional Comparative Study","Inclusion Criteria:\n\n* Singleton pregnancy\n* Diagnosis of fetal growth restriction (estimated fetal weight \\\u003C10th percentile for gestational age)\n* Written informed consent obtained from the patient\n\nExclusion Criteria:\n\n* Major fetal structural anomalies, especially cardiovascular anomalies\n* Multiple pregnancy (e.g., twins)\n* Suspected chromosomal abnormalities or genetic syndromes\n* Severe maternal comorbidities affecting Doppler results (e.g., uncontrolled diabetes, lupus)\n* Uncertain gestational age\n* Fetal demise before Doppler assessment","FEMALE","45 Years",{"count":114,"type":20},100,"This study aims to evaluate the patterns of aortic isthmus Doppler in fetuses diagnosed with early fetal growth restriction (FGR) and to correlate these findings with the severity of FGR and other Doppler parameters.\n\nA cross-sectional comparative observational study will be conducted on singleton pregnant women attending the fetal medicine unit at Assiut University Hospital. Participants will be divided into two groups: fetuses with FGR and normal controls.\n\nDoppler measurements including aortic isthmus indices, uterine artery, umbilical artery, middle cerebral artery, cerebroplacental ratio, and ductus venosus will be assessed at a single time point. The study will help to clarify the clinical value of aortic isthmus Doppler in early detection and assessment of fetal compromise in FGR cases.",[117,118,119,120],"Fetal Growth Restriction","Placental Insufficiency","Aortic Isthmus Doppler","Cerebroplacental Ratio","2026-06-27",{"date":98,"type":31},{"date":76,"type":20},{"date":125,"type":20},"2029-06-01",{"name":37,"class":38},{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":66,"sex":111,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":147,"leadSponsor":149,"locationsCount":84},"100632768","correlation-between-vaginal-laxity-and-delivery-mode-100632768","NCT07517978","Correlation Between Vaginal Laxity and Delivery Mode","Evaluation of Vaginal Laxity and Bladder Neck Descent in Parous Women Using 2D and 3D Transperineal Ultrasound","Inclusion Criteria:\n\n* parous women\n\nExclusion Criteria:\n\n* pregnant women\n* previous prolapse surgery",{"count":135,"type":20},150,"Evaluation of pelvic floor using 2D and 3D Transperineal Ultrasound",[138],"Vaginal Laxity",[140,141,142,143],"Transperineal Ultrasound","vaginal haitus","pelvic floor muscles","Bladder neck descent","2026-06-26",{"date":98,"type":31},{"date":144,"type":20},{"date":148,"type":20},"2027-12",{"name":37,"class":38},{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":111,"minAge":4,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":21,"phases":159,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":168,"startDateStruct":169,"completionDateStruct":170,"leadSponsor":172,"locationsCount":84},"100632939","comparison-between-3-conservative-surgeries-for-placenta-accreta-spectrum-100632939","NCT07520201","Comparison Between 3 Conservative Surgeries for Placenta Accreta Spectrum","Modified One Step Surgery vs. Segment Resection vs. Placental Bed Suturing for Management of Placenta Accreta Spectrum","Inclusion Criteria:\n\n* pregnant women with placenta accreta spectrum\n\nExclusion Criteria:\n\n* Patients refuse to share in the study\n* Pregnant \\\u003C 28 weeks",{"count":158,"type":20},42,[23],"Comparison between modified one-step surgery vs. Segment Resection vs. placental bed suturing for management of placenta accreta spectrum",[162],"Placenta Accreta Spectrum",[164,165,166,167],"Segment Resection","Modified one-step","Placental bed plication","Conservative uterine surgery",{"date":98,"type":31},{"date":144,"type":31},{"date":171,"type":20},"2027-07",{"name":37,"class":38},{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":182,"conditions":183,"keywords":187,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":4},"100645122","cognitive-function-and-quality-of-life-in-obstructive-sleep-apnea-100645122","NCT07678918","Cognitive Function and Quality of Life in Obstructive Sleep Apnea","Correlation Between the Cognitive Function and Quality of Life in Patients With OSA","Inclusion Criteria:\n\n* Patients Group: Age \\> 18 years.\n* Patients Group: Meeting the AASM diagnostic criteria for OSA.\n* Control Group: Age and sex-matched community members related to the patients.\n* Control Group: Education level, social status, and comorbidity-matched people.\n\nExclusion Criteria:\n\n* Patients Group: OSA patients who are compliant on PAP therapy (\\> 4 hours, \\> 5 nights\u002Fweek) for ≥ 6 months.\n* Patients Group: Inability to comprehend and\u002For co-operate with the instructions provided by the investigators during neurocognitive function assessment.\n* Patients Group: History of neurological comorbidities with potential cognitive impairment (previous cerebrovascular stroke, dementia).\n* Patients Group: Patients who are maintained on medications that potentially impair cognitive performance (histamine receptor antagonist, antipsychotic, antidepressant, or mood stabilizer drugs).\n* Patients Group: Use of alcohol, or illicit drugs that interfere with cognitive function (cannabis, opioids, amphetamine or equivalents).\n* Control Group: Intermediate or high-risk of having undiagnosed OSA as assessed by the STOP-BANG questionnaire.",{"count":181,"type":20},86,"Obstructive Sleep Apnea (OSA) is a common condition that disrupts normal breathing during sleep. Beyond causing daytime tiredness, OSA can also impact a person's cognitive functions, such as their attention span, memory, and problem-solving skills, which may in turn affect their overall quality of life.\n\nThe main purpose of this study is to compare the thinking and memory skills of adults recently diagnosed with OSA against a control group of healthy adults without the condition. Furthermore, the researchers aim to understand how specific cognitive challenges (like difficulty sustaining attention) relate to a patient's physical and mental well-being.\n\nParticipants in the study will undergo an overnight sleep test (diagnostic polysomnography) at a sleep clinic. Shortly after the sleep test, participants will complete a series of short, computer-based tasks designed to measure their attention, memory, and executive function. They will also be asked to fill out standard questionnaires regarding their daily sleepiness, mood, and health-related quality of life.",[184,185,186],"Obstructive Sleep Apnea","Cognitive Impairment","Quality of Life",[184,188,186,189,190,191,192],"Cognitive Function","Neurocognitive Impairment","Psychomotor Vigilance","Polysomnography","SF-36","2026-06-25",{"date":76,"type":31},{"date":196,"type":20},"2026-08",{"date":198,"type":20},"2027-09",{"name":37,"class":38},{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":207,"conditions":208,"keywords":213,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":218,"leadSponsor":220,"locationsCount":84},"100643993","correlation-between-ct-pulmonary-angiography-metrics-and-right-heart-catheterization-parameters-in-pre-capillary-pulmonary-hypertension-100643993","NCT07667595","Correlation Between CT Pulmonary Angiography Metrics and Right Heart Catheterization Parameters in Pre-Capillary Pulmonary Hypertension","Inclusion Criteria:\n\n1-Age ≥ 18 years at time of enrolment. 2-Confirmed pre-capillary pulmonary hypertension on RHC performed at Assiut University Hospital: mPAP \\> 20 mmHg AND PAWP ≤ 15 mmHg AND PVR ≥ 2 Wood Units.\n\n3-WHO PH Clinical Group 1 (PAH), Group 3 (PH due to lung disease\u002Fhypoxia), or Group 4 (CTEPH \u002F chronic thromboembolic PH) classification assigned by the PH-MDT.\n\n4-Both CTPA and RHC performed within a maximum interval of 4 weeks. b. Exclusion criteria:\n\n1. WHO PH Group 2 (PH due to left heart disease) or Group 5 (PH with unclear\u002Fmultifactorial mechanisms) .\n2. Active malignancy.\n3. Pregnancy, confirmed or suspected.\n4. Contraindication to iodinated contrast agent: eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m² OR documented history of severe anaphylactic contrast reaction.\n5. Inability to sustain breath-hold of ≥ 8 seconds (impairs CTPA quality).\n6. Initiation or dose escalation of pulmonary vasodilator therapy (endothelin receptor antagonist, PDE5 inhibitor, soluble guanylate cyclase stimulator, or prostanoid) in the interval between CTPA and RHC, or within 4 weeks prior to CTPA.\n7. Patient refusal to consent or inability to provide informed consent",{"count":70,"type":20},"Pulmonary hypertension (PH) is a hemodynamic and pathophysiological condition defined by a mean pulmonary artery pressure (mPAP) greater than 20 mmHg at rest, as confirmed by right heart catheterization (RHC) (1). The global prevalence of PH is estimated at approximately 1% of the adult population, rising to 10% or more in individuals over 65 years of age.Pre-capillary pulmonary hypertension, which includes pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), is characterized by a pulmonary arterial wedge pressure (PAWP) ≤15 mmHg and an elevated pulmonary vascular resistance (PVR) ≥2 Wood units (2)\n\nComputed tomography pulmonary angiography (CTPA) is routinely performed in the diagnostic workup of PH and offers a non invasive alternative that can generate multiple quantitative metrics from a single scan (3). Traditional CTPA metrics, including main pulmonary artery diameter (MPAd), the ratio of MPAd to ascending aortic diameter, central pulmonary arteries, and right ventricular to left ventricular diameter (RV\u002FLV ratio) were previously studied in PH patients (4,5,6) Most existing studies have evaluated CTPA metrics in isolation or within single PH subgroups, limiting generalizability across the broader pre-capillary PH population (7).\n\nTherefore, this study aims to systematically investigate the correlation between multiple quantitative CTPA metrics and key invasive hemodynamic parameters derived from RHC in patients with confirmed pre-capillary pulmonary hypertension",[209,210,211,212],"Pulmonary Hypertension","Precapillary Pulmonary Hypertension","Right Heart Catheterisation","CT Angiography",[214],"CTPA and RHC in precapillary PHTN","2026-06-24",{"date":193,"type":31},{"date":98,"type":20},{"date":219,"type":20},"2026-07-30",{"name":37,"class":38},{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":84},"100644038","predictors-and-outcomes-of-ventilated-hospital-acquired-pneumonia-100644038","NCT07667582","Predictors and Outcomes of Ventilated Hospital-acquired Pneumonia","Inclusion Criteria:\n\nAll patients diagnosed with HAP in the chest department, Assiut University\n\nExclusion Criteria:\n\n1. Post operative patients\n2. Tracheostomized patients\n3. Comatosed patient since admission\n4. Suspected aspiration","100 Years",{"count":229,"type":20},151,"Hospital-acquired pneumonia (HAP) is defined as an infection of the pulmonary parenchyma that develops in patients admitted to hospital for more than 48 hours and that was not incubating at the time of admission. It represents one of the most common and serious nosocomial infections, associated with significant morbidity, prolonged hospitalisation, and increased mortality in critically ill patients.\n\nThe aetiology of HAP is primarily driven by micro-aspiration of bacteria colonising the oropharynx and upper gastrointestinal tract. Pathogen distribution is shaped by the duration of hospitalisation, prior antibiotic exposure, local epidemiology, and patient characteristics. Multidrug-resistant (MDR) organisms are particularly prevalent in patients with prolonged inpatient stay and intensive care unit (ICU) admission, as critically ill patients become rapidly colonised with nosocomial pathogens.\n\nVentilator-associated pneumonia (VAP), a subgroup of nosocomial pneumonia, occurs in patients requiring tracheal intubation and mechanical ventilation for at least 48 hours. A clinically important and increasingly recognised entity is ventilated HAP (v-HAP), defined as HAP that subsequently requires tracheal intubation and mechanical ventilation. Emerging evidence indicates that v-HAP carries the highest mortality among nosocomial pneumonia subtypes in ICU patients - exceeding VAP - while non-ventilated ICU-acquired HAP carries the lowest mortality.",[232],"Hospital Acquired Pneumonia",[234,235],"HAP","ventilated HAP",{"date":193,"type":31},{"date":238,"type":31},"2026-06-01",{"date":240,"type":20},"2027-06-30",{"name":37,"class":38},{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":66,"sex":16,"minAge":67,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":21,"phases":252,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":260,"leadSponsor":262,"locationsCount":4},"100644484","phase-4-intraperitoneal-ketamine-versus-fentanyl-as-adjuvants-to-bupivacaine-in-laparoscopic-cholecystectomy-100644484","NCT07670052","Intraperitoneal Ketamine Versus Fentanyl as Adjuvants to Bupivacaine in Laparoscopic Cholecystectomy","Intraperitoneal Instillation of Ketamine Versus Fentanyl as Adjuvants to Bupivacaine for Postoperative Pain Control in Laparoscopic Cholecystectomy _a Double-blinded Randomized Trial.","Inclusion Criteria:\n\n* Patients of age 20-50 years\n* Patients of either gender\n* Patients planned to undergo elective LC.\n* Patients have I-II of the American Society of Anaesthesiologists (ASA)\n\nExclusion Criteria:\n\n* Patient's refusal.\n* body mass index (BMI) ≥40 kg\u002Fm2.\n* History of hypersensitivity to the drugs being evaluated\n* Inability to comprehend postoperatively the pain assessment scale\u002Fneuropsychiatric disorders.\n* chronic use of opioids and opioid addiction\n* Patients with acute cholecystitis or converted to open surgery.\n* Carcinoma of gall bladder\n* Pregnant female\n* Bleeding disorders","50 Years",{"count":251,"type":20},84,[253],"PHASE4","Laparoscopic cholecystectomy is the standard surgical treatment for gallbladder stones; however, the origin of pain after LC is multifactorial and complex in nature. Pain arising from incision sites is parietal pain, whereas pain from the gall bladder bed is mainly visceral in nature, and shoulder pain is mainly referred owing to the residual carbon dioxide irritating the diaphragm. Intraperitoneal administration of local anesthetics has been shown to improve postoperative pain control and reduce the need for systemic analgesics. The addition of adjuvant agents such as fentanyl or ketamine may further enhance analgesic efficacy. This randomized double-blind study aims to compare the effectiveness of intraperitoneal ketamine versus fentanyl as adjuvants to bupivacaine in reducing postoperative pain and analgesic requirements following laparoscopic cholecystectomy.",[256],"Postoperative Pain","2026-06-23",{"date":144,"type":31},{"date":102,"type":20},{"date":261,"type":20},"2027-09-01",{"name":37,"class":38},{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":66,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":4},"100643884","ultrasound-assessment-of-diaphragmatic-structure-and-function-in-patients-with-liver-cirrhosis-a-point-of-care-tool-for-predicting-complications-and-sarcopenia-in-limited-resource-settings-100643884","NCT07667608","Ultrasound Assessment of Diaphragmatic Structure and Function in Patients With Liver Cirrhosis: A Point-of-Care Tool for Predicting Complications and Sarcopenia in Limited Resource Settings","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Confirmed diagnosis of liver cirrhosis based on clinical, biochemical, histological, or imaging criteria.\n3. Ability to provide written informed consent in Arabic or English.\n4. For Subgroup A: clinical indication for large-volume paracentesis with an ascitic volume of ≥5 liters.\n5. For Subgroup B: confirmed hepatic hydrothorax or confirmed absence of pleural effusion on ultrasound or chest X-ray.\n6. For Subgroup C: radiologically confirmed HCC by triphasic CT or MRI according to EASL\u002FAASLD diagnostic criteria, with available CT imaging for L3 SMI analysis.\n\nExclusion Criteria:\n\n1. Significant pre-existing primary pulmonary disease (e.g., moderate-to-severe COPD defined as FEV1\u002FFVC \\\u003C70% with FEV1 \\\u003C60% predicted, interstitial lung disease, pulmonary fibrosis) that independently affects diaphragmatic mechanics.\n2. Recent thoracic surgery, thoracocentesis within the preceding 72 hours, or thoracic trauma.\n3. Neuromuscular disease (e.g., myasthenia gravis, amyotrophic lateral sclerosis, Guillain-Barré syndrome) independently affecting diaphragmatic function.\n4. Active mechanical ventilation at time of enrollment.\n5. Pregnancy.\n6. Inability to achieve adequate ultrasound acoustic windows (e.g., due to extreme obesity or surgical dressings).\n7. Contraindications to paracentesis in Subgroup A (e.g., disseminated intravascular coagulation, bowel obstruction).\n8. Prior or planned liver transplantation within the study period, which would confound longitudinal follow-up.\n9. Refusal or inability to provide informed consent.",{"count":270,"type":20},120,"The goal of this observational study is to learn how liver cirrhosis affects the diaphragm, the main muscle used for breathing, in adults. The study will measure diaphragmatic thickness, thickening fraction, and excursion using bedside ultrasound and compare these values between patients with cirrhosis and healthy volunteers. The main questions it aims to answer are:\n\nDo patients with cirrhosis show reduced diaphragmatic function compared to healthy adults?\n\nDoes removal of ascitic fluid by paracentesis improve diaphragmatic mechanics?\n\nCan ultrasound measurements of the diaphragm serve as a reliable non-invasive marker of sarcopenia when compared to CT scans?\n\nParticipants will:\n\nUndergo diaphragmatic ultrasound during quiet and deep breathing\n\nProvide clinical and laboratory data related to liver disease severity\n\nIn some cases, have ultrasound repeated before and after paracentesis\n\nFor patients with hepatocellular carcinoma, CT scans will be analyzed to measure muscle mass",[273,274,275,276,277,278],"Cirrhosis of the Liver","Ascites","Pleural Effusion Disorder","Hepatocellular Carcinoma (HCC)","Sarcopenia","Diaphragm Movement","2026-06-19",{"date":193,"type":31},{"date":282,"type":20},"2026-08-10",{"date":284,"type":20},"2027-12-10",{"name":37,"class":38},{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":16,"minAge":293,"maxAge":294,"enrollmentInfo":295,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":296,"conditions":297,"keywords":300,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":310,"completionDateStruct":311,"leadSponsor":312,"locationsCount":4},"100644464","cbc-indices-and-serum-lactate-in-neonatal-sepsis-100644464","NCT07663084","CBC Indices and Serum Lactate in Neonatal Sepsis","Diagnostic and Prognostic Values of CBC Indices and Serum Lactate in Neonatal Sepsis","Inclusion Criteria:\n\n* Neonates aged 0 to 28 days (term and preterm).\n* Presence of two or more clinical signs highly suggestive of sepsis (e.g., temperature instability \\[\\\u003C 36.5°C or \\> 37.5°C\\], tachycardia\u002Fbradycardia, tachypnea, feeding intolerance, lethargy, or altered muscle tone).\n* Informed written consent obtained from the parents or legal guardians.\n\nExclusion Criteria:\n\n* Neonates with severe congenital anomalies or chromosomal abnormalities.\n* Neonates diagnosed with Inborn Errors of Metabolism (which inherently alter lactate levels).\n* Neonates with severe perinatal asphyxia or Hypoxic-Ischemic Encephalopathy (HIE), as these conditions cause profound primary lactic acidosis independent of sepsis.\n* Neonates who received prior broad-spectrum intravenous antibiotics for more than 24 hours prior to admission.\n* Neonates who have received prior blood transfusions.\n* Neonates requiring immediate surgical intervention.","0 Days","28 Days",{"count":47,"type":20},"Neonatal sepsis is a leading cause of illness and death in Neonatal Intensive Care Units (NICUs). Diagnosing it quickly is challenging because the early signs often overlap with other common newborn health issues. While a blood culture is the most accurate way to confirm an infection, the results can take 48 to 72 hours. This delay highlights the need for faster, more accessible diagnostic tools.\n\nThis observational study aims to find quicker ways to diagnose neonatal sepsis and predict its severity using readily available blood tests. Researchers are investigating whether specific details from a standard Complete Blood Count (CBC), such as the variation in red blood cell size (RDW), the average size of platelets (MPV), and the ratio of immature to total white blood cells (I\u002FT ratio), combined with serum lactate levels (a marker of tissue oxygenation and stress) can serve as reliable, early warning signs.\n\nThe study will enroll newborns (0 to 28 days old) admitted to the NICU who show clinical signs of a possible infection. Upon admission and before starting any antibiotic treatment, a small blood sample will be drawn to measure these CBC indices and serum lactate, alongside the standard blood culture.\n\nBy comparing these rapid blood test results with the final blood culture outcomes and the infants' overall clinical progress in the NICU, the research team hopes to determine if this simple combination of markers can help doctors diagnose sepsis earlier, anticipate the severity of the illness, and make faster, life-saving treatment decisions.",[298,299],"Neonatal Sepsis","Sepsis",[298,301,302,303,304,305,306,307],"Complete Blood Count Indices","Serum Lactate","Mean Platelet Volume","Immature-to-Total Neutrophil Ratio","Red Cell Distribution Width","Diagnostic Biomarkers","Prognosis","2026-06-17",{"date":257,"type":31},{"date":196,"type":20},{"date":198,"type":20},{"name":37,"class":38},{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":12,"sex":111,"minAge":17,"maxAge":321,"enrollmentInfo":322,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":324,"conditions":325,"keywords":329,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":342,"leadSponsor":344,"locationsCount":84},"100641313","hippo-related-competing-endogenous-rna-cerna-network-dysregulation-and-in-vitro-fertilization-ivf-outcomes-in-women-with-diminished-ovarian-reserve-100641313","NCT07658846","Hippo-Related Competing Endogenous RNA (ceRNA) Network Dysregulation and In Vitro Fertilization (IVF) Outcomes in Women With Diminished Ovarian Reserve","Investigating the Dysregulation of the Hippo-Related ceRNA Network and Its Impact on IVF Outcomes in Patients With Diminished Ovarian Reserve (DOR)","DOR-HIPPO-IVF","Inclusion Criteria:\n\n* Women undergoing In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) cycles.\n* Infertility duration of at least one year\n* Primary or secondary infertility.\n\nExclusion Criteria:\n\n* Polycystic Ovary Syndrome (PCOS)\n* Endometriosis.\n* Ovarian tumors or malignancy.\n* Severe systemic diseases affecting fertility.\n* Metabolic syndrome.\n* Connective tissue disorders.\n* Hormonal therapy within the last three months.\n* Refusal to participate.","40 Years",{"count":323,"type":20},70,"Diminished Ovarian Reserve (DOR) is an important cause of female infertility and is associated with poor ovarian response and lower pregnancy rates during In Vitro Fertilization (IVF). The molecular mechanisms underlying impaired follicular development in DOR remain incompletely understood. Increasing evidence suggests that non-coding RNAs and components of the Hippo signaling pathway play important roles in granulosa cell proliferation, apoptosis, and follicular development.\n\nThis prospective observational cohort study aims to investigate the expression of the long non-coding RNA (lncRNA) Nuclear Paraspeckle Assembly Transcript 1 (NEAT1), microRNA (miRNA)-181a-5p, Hippo pathway components including Yes-Associated Protein 1 (YAP1) and Connective Tissue Growth Factor (CTGF), and Insulin-Like Growth Factor 1 (IGF1) in follicular fluid-derived cells from women with DOR undergoing IVF compared with women with normal ovarian reserve. The study will also evaluate relationships among these molecular markers and IVF outcomes, including oocyte quality, number of retrieved oocytes, and embryo developmental potential.",[326,327,328],"Diminished Ovarian Reserve","Female Infertility","In Vitro Fertilization",[330,331,332,333,334,335,336,337,338],"Diminished Ovarian Reserve (DOR)","In Vitro Fertilization (IVF)","Hippo Signaling Pathway","Nuclear Paraspeckle Assembly Transcript 1 (NEAT1)","microRNA-181a-5p","Yes-Associated Protein 1 (YAP1)","Connective Tissue Growth Factor (CTGF)","Insulin-Like Growth Factor 1 (IGF1)","Follicular Fluid",{"date":340,"type":31},"2026-06-22",{"date":102,"type":20},{"date":343,"type":20},"2028-10-01",{"name":37,"class":38},{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":353,"conditions":354,"keywords":359,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":4},"100641054","musculoskeletal-ultrasound-for-differentiating-rheumatoid-and-gouty-arthritis-100641054","NCT07657156","Musculoskeletal Ultrasound for Differentiating Rheumatoid and Gouty Arthritis","Role of Musculoskeletal Ultrasound in Differentiation of Rheumatoid Arthritis and Gouty Arthritis Using Semi-Quantitative Scoring","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Either sex.\n* Patients with clinically suspected or confirmed rheumatoid arthritis.\n* Patients with clinically suspected or confirmed gouty arthritis.\n* Patients referred for musculoskeletal ultrasound assessment of painful, swollen, or inflamed joints.\n* Patients able and willing to provide informed consent.\n* Patients whose final diagnosis is established by clinical assessment, laboratory testing, and\u002For relevant imaging or synovial fluid analysis when available.\n\nExclusion Criteria:\n\n* Patients younger than 18 years.\n* Patients with septic arthritis or suspected joint infection.\n* Patients with traumatic joint injury involving the target joint.\n* Patients with other inflammatory arthropathies such as psoriatic arthritis, reactive arthritis, or systemic lupus erythematosus if they may confound imaging interpretation.\n* Patients with advanced osteoarthritis in the scanned joint if it markedly limits Faculty of Medicine Institutional Review Board (IRB) Assiut Medical School Research Proposal Form 5 interpretation.\n* Patients with incomplete clinical records or insufficient ultrasound windows.\n* Patients who refuse consent.\n* Patients whose diagnosis remains uncertain after clinical workup.",{"count":114,"type":20},"Rheumatoid arthritis (RA) and gouty arthritis (GA) are two common forms of joint inflammation that can present with very similar physical symptoms, making them difficult to tell apart early in the disease process. Accurate and early differentiation is crucial because the treatment strategies and long-term management for the two conditions are substantially different.\n\nThe primary purpose of this observational study is to evaluate the diagnostic performance of musculoskeletal ultrasound (MSUS) in distinguishing between RA and GA. Ultrasound is a safe, radiation-free imaging tool that can visualize joint inflammation and structural changes in real-time. This study utilizes a structured semi-quantitative scoring system (graded on a scale of 0 to 3) to systematically measure the severity of joint lining thickness (synovial hypertrophy) and active blood flow (power Doppler signal). It also checks for crystal-related deposits, such as tophi or the double contour sign, which are highly suggestive of gout.\n\nParticipants aged 18 and older with suspected or confirmed RA or GA who are referred for joint assessment at Assiut University Hospitals will undergo a standard clinical evaluation, routine laboratory testing, and an ultrasound examination of specific target joints (such as the wrists, hands, knees, and ankles). By comparing the ultrasound scores and specific structural findings between the two patient groups, the study aims to establish a reliable, standardized imaging approach to help physicians make faster, more confident diagnoses and initiate the correct disease-specific therapies sooner.",[355,356,357,358],"Rheumatoid Arthritis (RA)","Gouty Arthritis (GA)","Gout","Inflammatory Arthritis",[360,361,362,363,364,365,366,367],"Musculoskeletal Ultrasound","Semi-quantitative Scoring","Ultrasonography","Synovitis","Power Doppler","Double Contour Sign","Tophi","Diagnostic Imaging","2026-06-14",{"date":370,"type":31},"2026-06-18",{"date":372,"type":20},"2026-07",{"date":374,"type":20},"2027-08",{"name":37,"class":38},{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":382,"enrollmentInfo":383,"targetDuration":4,"studyType":21,"phases":385,"briefSummary":386,"conditions":387,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":391,"completionDateStruct":392,"leadSponsor":394,"locationsCount":4},"100641114","inferior-mesenteric-artery-first-combined-with-complete-medial-approach-for-laparoscopic-splenic-flexure-mobilization-in-left-sided-colorectal-cancer-100641114","NCT07655856","Inferior Mesenteric Artery First Combined With Complete Medial Approach for Laparoscopic Splenic Flexure Mobilization in Left Sided Colorectal Cancer","Inclusion Criteria:\n\nPatients aged 18-70 years old with confirmed colorectal cancer diagnosis by histopathology with obligatory splenic flexure mobilization and had laparoscopic surgery with curative intent were included.\n\nExclusion Criteria:\n\n* Those younger than 18 years or older than 70 years.\n* Those undergoing non-cancer resections, or completion surgery or palliative procedures.\n* Those with locally advanced ( extra colonic extension ) or metastatic tumors.\n* Those with advanced comorbidities ( laparoscopy is contraindicated )","70 Years",{"count":384,"type":20},68,[23],"The aim of the study to compare surgical outcomes between inferior mesenteric artery first with complete medial approach and other traditional techniques in laparoscopic left sided colorectal cancer .",[388],"Laparoscopic Splenic Flexure Mobilization","2026-06-13",{"date":370,"type":31},{"date":372,"type":20},{"date":393,"type":20},"2029-05",{"name":37,"class":38},{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":66,"sex":16,"minAge":402,"maxAge":17,"enrollmentInfo":403,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":404,"conditions":405,"keywords":407,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":409,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":4},"100641292","cardiovascular-abnormalities-in-children-with-attention-deficithyperactivity-disorder-100641292","NCT07655843","Cardiovascular Abnormalities in Children With Attention-deficit\u002FHyperactivity Disorder","Cardiovascular Abnormalities in Children With Attention-deficit\u002FHyperactivity Disorder Attending Assiut University Children Hospital: A Case Control Study","Inclusion Criteria:\n\nCase group :\n\n* Age is \\> 6 years and \\\u003C18 years old\n* Both sex\n* Patients diagnosed as having ADHD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.\n* Currently receiving pharmacological treatment for at least six months\n\nControl group:\n\nHealthy, typically developing children , matched by age and sex to the case group\n\n\\-\n\nExclusion Criteria:\n\n* Age \\> 18 years\n* Patients who have a history of chronic diseases.\n* Patients with established hereditary syndromes or chromosomal abnormalities as Down syndrome.","6 Years",{"count":114,"type":20},"To identify the prevalence and types of cardiovascular abnormalities in children diagnosed with ADHD",[406],"ADHD - Combined Type",[408],"cardiovascular abnormalities",{"date":370,"type":31},{"date":411,"type":20},"2026-06-15",{"date":413,"type":20},"2028-04-15",{"name":37,"class":38},{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":66,"sex":111,"minAge":67,"maxAge":423,"enrollmentInfo":424,"targetDuration":4,"studyType":21,"phases":426,"briefSummary":429,"conditions":430,"keywords":432,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":436,"leadSponsor":438,"locationsCount":84},"100641628","phase-1-effect-of-gnrh-agonist-in-fet-100641628","NCT07653282","Effect of GnRH Agonist in FET","Single Dose of Gonadotropin Releasing Hormone (GnRH)-Agonist as an Adjuvant Luteal Phase Support in Hormone Replacement Therapy (HRT) Frozen Embryo Transfer (FET) Cycles Prospective Comparative Study","gnrh agonist","Inclusion Criteria:\n\n* 1\\. Age 20-39 years 2. Undergoing HRT-FET cycle 3. ≥1 good quality embryo available , Gardner ≥3BB 4. Endometrial thickness ≥7mm on day of progesterone start 5. BMI 18-35 kg\u002Fm² 6. First or second FET cycle 7. Written informed consent\n\nExclusion Criteria:\n\n* 1\\. History of recurrent implantation failure ≥3 failed embryo transfers 2. Severe endometriosis Stage III-IV by ASRM 3. Uterine anomalies, submucous fibroid, or severe adenomyosis distorting cavity 4. History of recurrent pregnancy loss ≥2 consecutive 5. Contraindication or hypersensitivity to GnRH agonist 6. PGT-A cycles 7. Donor oocyte cycles","39 Years",{"count":425,"type":20},122,[427,428],"PHASE1","PHASE2","To evaluate the impact of single dose GnRH agonist administration as luteal phase support on pregnancy outcomes in frozen ICSI cycle",[431],"GnRH Agonist",[421],"2026-06-12",{"date":308,"type":31},{"date":102,"type":20},{"date":437,"type":20},"2028-08-01",{"name":37,"class":38},{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":21,"phases":448,"briefSummary":449,"conditions":450,"keywords":452,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":459,"leadSponsor":460,"locationsCount":84},"100642464","smoking-cessation-counseling-performance-among-medical-interns-100642464","NCT07650721","Smoking Cessation Counseling Performance Among Medical Interns","Effect of Artificial Intelligence-Assisted Interactive Case-Based Training on Smoking Cessation Counseling Performance Among Medical Interns","Inclusion Criteria:\n\n* Medical interns enrolled in the internship training program at the Faculty of Medicine, Assiut University during the study period.\n* Able to attend the training session and complete all study assessments, including the pre-test and post-test evaluations.\n\nExclusion Criteria:\n\n* Previous formal structured training in smoking cessation counseling based on the 5A model.\n* Previous participation in a smoking cessation counseling educational program within the preceding 12 months.\n* Failure to complete the assigned educational intervention.\n* Failure to complete either the pre-test or post-test assessment.\n* Withdrawal of consent at any stage of the study.",{"count":447,"type":20},140,[23],"Smoking remains one of the leading preventable causes of morbidity and mortality worldwide and is strongly associated with chronic respiratory diseases, cardiovascular disease, cancer, and premature death. Physicians play a central role in tobacco control through the delivery of smoking cessation counseling, and even brief physician advice has been shown to significantly increase smoking quit rates. The evidence-based 5A's model (Ask, Advise, Assess, Assist, and Arrange) is widely recommended as the standard framework for smoking cessation counseling.",[451],"Smoking Cessation",[451,453,454],"Artificial Intelligence","Medical Interns","2026-06-11",{"date":457,"type":31},"2026-06-16",{"date":98,"type":20},{"date":33,"type":20},{"name":37,"class":38},{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":12,"sex":111,"minAge":17,"maxAge":112,"enrollmentInfo":468,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":470,"conditions":471,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":474,"leadSponsor":475,"locationsCount":4},"100642021","maternal-and-fetal-outcomes-in-elective-vs-emergency-cesarean-section-100642021","NCT07651241","Maternal and Fetal Outcomes in Elective vs Emergency Cesarean Section","Maternal and Fetal Outcomes in Elective and Emergency Cesarean Section in Women's Health Hospital","Inclusion Criteria:\n\n* 1- Pregnant women undergoing cesarean section 2- Singleton pregnancy 3- Gestational age ≥ 28 weeks 4- Age 18-45 years\n\nExclusion Criteria:\n\n* 1- Multiple pregnancy 2- Known fetal anomalies 3- Intrauterine fetal demise before cesarean section 4- Severe maternal comorbidities (e.g., cardiac disease, renal failure) 5- Rupture uterus 6- patients with placenta previa or accreta spectrum",{"count":469,"type":20},210,"Cesarean section (CS) rates have increased substantially worldwide and in Egypt, where they now account for the majority of deliveries. Maternal and neonatal outcomes may differ between elective and emergency CS. Emergency cesarean sections are generally associated with higher maternal morbidity, including increased risks of postpartum hemorrhage, infection, blood transfusion, longer operative time, and prolonged hospital stay. Neonatal outcomes following emergency CS may also be less favorable, with higher rates of low Apgar scores, respiratory distress, and NICU admission. However, findings remain inconsistent across studies, highlighting the need for further prospective research to comprehensively compare maternal and fetal outcomes between elective and emergency cesarean deliveries.",[465],{"date":457,"type":31},{"date":76,"type":20},{"date":261,"type":20},{"name":37,"class":38},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":482,"targetDuration":4,"studyType":21,"phases":483,"briefSummary":484,"conditions":485,"keywords":487,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":493,"completionDateStruct":494,"leadSponsor":496,"locationsCount":4},"100641962","arthroscopic-versus-open-management-of-lateral-epicondylitis-elbow-randomized-control-trial-100641962","NCT07648849","Arthroscopic Versus Open Management of Lateral Epicondylitis Elbow (Randomized Control Trial)","Inclusion Criteria:\n\n* tennis elbow not responding to conservative measures (more than 6 months) adult population (more than 18 years)\n\nExclusion Criteria:\n\n* Degenerative changes of the elbow (as inflammatory diseases) Previously operated cases Disorganized anatomy of the joint (as in posttraumatic cases) neurovascular compromise of the upper limb",{"count":19,"type":20},[23],"Arthroscopic Versus Open management of lateral epicondylitis elbow (Randomized Control Trial)",[486],"Tennis Elbow",[488,489,490],"tennis elbow","lateral epicondylitis","arthroscopy","2026-06-10",{"date":411,"type":31},{"date":455,"type":20},{"date":495,"type":20},"2028-06-11",{"name":37,"class":38},{"id":498,"slug":499,"hasResults":12,"nctId":500,"briefTitle":501,"officialTitle":502,"acronym":4,"eligibilityCriteria":503,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":506,"conditions":507,"keywords":510,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":514,"leadSponsor":515,"locationsCount":84},"100642645","assessment-of-peripheral-neuropathy-in-ankylosing-spondylitis-100642645","NCT07641920","Assessment of Peripheral Neuropathy in Ankylosing Spondylitis","Assessment of Peripheral Neuropathy in Ankylosing Spondylitis and Its Correlation With, Central Sensitization, Disease Activity and Quality of Life","Inclusion Criteria:\n\n* Patients aged ≥18 years\n* Diagnosis of ankylosing spondylitis according to the modified New York criteria (6).\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Patients under the age of 18 years.\n* Patients with definite diagnosis for any other systemic autoimmune disorders.\n* Diabetes mellitus\n* Chronic renal or hepatic disease\n* Alcohol abuse or drug-induced neuropathy\n* Known neurological disorders affecting peripheral nerves",{"count":505,"type":20},45,"investigators hypothesized that peripheral neuropathy in ankylosing spondylitis is associated with higher disease activity, greater central sensitization, worse functional impairment, and poorer quality of life.",[508,509],"Ankylosing Spondylitis","Peripheral Neuropathies",[508,186,511],"Peripheral Neuropathy",{"date":433,"type":31},{"date":98,"type":20},{"date":33,"type":20},{"name":37,"class":38},{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":66,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":523,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":525,"conditions":526,"keywords":528,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":534,"leadSponsor":535,"locationsCount":4},"100641821","evaluation-of-serum-il-41-level-in-patients-with-ankylosing-spondylitis-and-psoriatic-arthritis-100641821","NCT07648836","Evaluation of Serum IL-41 Level in Patients With Ankylosing Spondylitis and Psoriatic Arthritis","Evaluation of Serum IL-41 Level in Patients With Ankylosing Spondylitis and Psoriatic Arthritis and Their Association With Inflammatory Markers and Disease Activity","Inclusion Criteria:\n\n* patients diagnosed with ankylosing spondylitis (AS)and psoriatic arthritis (PsA), in addition to age- and sex-matched healthy controls.\n\nAS diagnosed according to the modified New York criteria, while PsA was diagnosed based on the CASPAR criteria.\n\nExclusion Criteria:\n\nPatients under the age of 18 years, patients with other autoimmune diseases, diabetes mellitus, chronic kidney or liver disease, active infection, or malignancy were excluded to avoid confounding factors affecting inflammatory markers.",{"count":524,"type":20},90,"Psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are chronic inflammatory diseases within the spectrum of spondyloarthritis, characterized by immune-mediated inflammation and progressive functional impairment. Meteorin-like protein (Metrnl) is a novel adipomyokine with potential immunomodulatory and anti-inflammatory properties; however, its role in spondyloarthritis remains incompletely understood. This study aims to evaluate serum Metrnl levels in patients with PsA and AS compared with healthy controls and to investigate their association with disease activity, inflammatory markers, and clinical manifestations. The findings may provide insights into the potential role of Metrnl as a biomarker of disease activity and inflammation in spondyloarthritis.",[508,527],"Psoriasis",[529,530,531],"Ankylosing spondylitis","psoriasis","biomarker",{"date":411,"type":31},{"date":76,"type":20},{"date":219,"type":20},{"name":37,"class":38},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":542,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":546,"conditions":547,"keywords":549,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":557,"completionDateStruct":558,"leadSponsor":559,"locationsCount":84},"100643066","urinary-pge-mum-as-a-marker-for-ulcerative-colitis-activity-100643066","NCT07637045","Urinary PGE-MUM as a Marker for Ulcerative Colitis Activity","Urinary Prostaglandin E-Major Metabolite (PGE-MUM) Discriminates Disease Activity in Ulcerative Colitis: A Cross-Sectional Study From Egypt","PGE-MUM_UC","Inclusion Criteria:\n\n* Adult patients aged ≥18 years\n* Confirmed diagnosis of Ulcerative Colitis based on clinical, endoscopic, and histopathological criteria\n* Active disease (Mayo Endoscopic Score 2-3, Clinical Activity Index ≥4) OR remission (Mayo Endoscopic Score 0-1, Clinical Activity Index ≤3)\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Patients with other types of colitis (e.g., Crohn's disease, infectious colitis, ischemic colitis)\n* History of colectomy\n* Current smokers\n* Chronic lung disease\n* Malignancy\n* Use of laxatives or NSAIDs within 2 weeks prior to enrollment\n* Chronic kidney disease\n* Pregnancy or lactation\n* Active infection",{"count":545,"type":20},114,"Ulcerative colitis (UC) is a chronic inflammatory bowel disease that requires regular monitoring of disease activity. Currently, assessment depends on invasive colonoscopy or clinical scores that may not accurately reflect intestinal inflammation. This study aims to evaluate whether urinary Prostaglandin E-Major Metabolite (PGE-MUM) can serve as a non-invasive biomarker to discriminate disease activity in patients with ulcerative colitis.\n\nThis cross-sectional study will be conducted at Al-Rajhi University Hospital, Assiut University, Egypt.This study plans to enroll 114 adult patients (≥18 years) with confirmed UC diagnosis, divided into two equal groups: active disease and remission (57 patients each). Disease activity will be assessed using the Mayo Endoscopic Score (MES) and Clinical Activity Index (CAI). Urine samples will be collected from all participants to measure PGE-MUM levels. Blood samples will be tested for CRP, CBC, albumin, and creatinine. Colonoscopy with biopsy will be performed for endoscopic scoring and histopathological assessment using Geboes score.\n\nThe primary outcome is to establish urinary PGE-MUM as a validated discriminatory biomarker for distinguishing active disease from remission in Egyptian patients with UC. Secondary outcomes include comparing PGE-MUM with CRP, determining the optimal cut-off value, and correlating PGE-MUM levels with MES and Geboes score.\n\nIf successful, urinary PGE-MUM could provide a simple, non-invasive, and cost-effective method for monitoring UC activity in the Egyptian healthcare setting, reducing the need for frequent colonoscopies and overcoming cultural barriers associated with stool collection.",[548],"Ulcerative Colitis (UC)",[550,551,552,553,554],"Ulcerative Colitis","PGE-MUM","Urinary biomarker","Inflammatory Bowel Disease","Non-invasive biomarker","2026-06-09",{"date":455,"type":31},{"date":102,"type":20},{"date":240,"type":20},{"name":37,"class":38},{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":4,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":567,"targetDuration":4,"studyType":21,"phases":569,"briefSummary":571,"conditions":572,"keywords":575,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":585,"completionDateStruct":586,"leadSponsor":587,"locationsCount":4},"100643163","phase-3-nebulized-versus-intravenous-tranexamic-acid-for-the-management-of-hemoptysis-100643163","NCT07641946","Nebulized Versus Intravenous Tranexamic Acid for the Management of Hemoptysis","Nebulized Versus Intravenous Tranexamic Acid for the Management of Hemoptysis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥18 years.\n* Presenting with active hemoptysis 24-48 hours prior to enrollment, or ongoing bleeding at presentation.\n* Patients presented with mild to moderate hemoptysis, defined as \\\u003C100 mL\u002Fday, or with clinically stable non-massive hemoptysis without evidence of respiratory or hemodynamic compromise.\n* Hemodynamically stable at presentation defined as systolic blood pressure ≥90 mmHg without vasopressor support, heart rate ≤120 beats\u002Fmin, and absence of clinical signs of shock or ongoing hemodynamic deterioration.\n* Patients able to maintain a patent airway, tolerate nebulized therapy, and have no immediate contraindications (e.g., severe bronchospasm, impaired consciousness with aspiration risk, or need for urgent intubation), ensuring safe and effective drug delivery.\n* Written informed consent obtained from the patient.\n\nExclusion Criteria:\n\n* Massive or life-threatening hemoptysis defined as expectoration of \\>100 mL of blood within 24 hours, or any volume associated with impaired gas exchange, airway obstruction, or hemodynamic instability requiring urgent intervention (e.g., bronchoscopy, bronchial artery embolization, endotracheal intubation, or surgery).\n* Hemodynamic instability which defined as SBP \\\u003C90 mmHg or MAP \\\u003C65 mmHg, need for vasopressor support, or clinical evidence of end-organ hypoperfusion or shock.\n* Respiratory failure requiring immediate invasive mechanical ventilation.\n* Patients known with hypersensitivity to tranexamic acid.\n* Patients receiving ongoing anticoagulant therapy that can interfere with the antifibrinolytic effect of tranexamic acid.\n* Patients with known bleeding disorders, severe coagulopathy, or thrombocytopenia (platelet count \\\u003C50,000\u002Fmm³).\n* Patients with severe renal impairment (e.g., estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m² or requiring dialysis).\n* Patients with active thromboembolic disease or a recent history (within the past 3-6 months) of deep vein thrombosis, pulmonary embolism, ischemic stroke, or myocardial infarction.\n* Pregnancy or lactation.",{"count":568,"type":20},170,[570],"PHASE3","This clinical trial aims to compare two different ways of giving a medication called tranexamic acid to patients who are coughing up blood (a condition known as hemoptysis). Coughing up blood can be a serious medical issue that needs to be stopped quickly. Tranexamic acid is a well-known medication that helps blood to clot and stops bleeding.\n\nUsually, this medication is given through an intravenous (IV) line directly into a vein. However, doctors are now studying if giving the medication through a breathing mask (nebulizer) might work just as well or better. A nebulizer changes the liquid medicine into a fine mist so the patient can breathe it directly into their lungs, targeting the exact area where the bleeding is happening.\n\nTo find out which method is better, researchers will randomly assign 170 adult patients who come to the hospital coughing up blood into two equal groups:\n\nGroup 1: Will receive the tranexamic acid medication inhaled through a nebulizer mask.\n\nGroup 2: Will receive the tranexamic acid medication through a standard IV line.\n\nThe main goal of the study is to see which treatment is more successful at completely stopping the bleeding within 24 hours. Researchers will also closely monitor the patients to see how quickly the bleeding stops, how long patients need to stay in the hospital, and if there are any side effects from either treatment method.",[573,574],"Hemoptysis","Pulmonary Hemorrhage",[576,577,578,579,580,581,582],"Tranexamic Acid","Nebulized Tranexamic Acid","Intravenous Tranexamic Acid","Antifibrinolytic Agents","Inhalational Therapy","Active Bleeding","Airway Management","2026-06-08",{"date":455,"type":31},{"date":372,"type":20},{"date":374,"type":20},{"name":37,"class":38},""]